# US 2001/0025029 A1 · Novel stromelysin inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025029 A1
- Document ID: US20010025029A1
- Status: Published application
- Kind: A1
- Application number: 09/736,382
- Filed: 2000-12-15
- Published: 2001-09-27
- Earliest claimed: 1999-12-16
- Inventors: Cordula Hopmann; Martin Albert Knauf; Klaus-Ulrich Weithmann; Joachim Wink
- Web page: https://patentgrep.com/patent/US20010025029A1

## CPC

- C07H 7/04: Carbocyclic radicals
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the formula I 1 are suitable for the production of pharmaceuticals for the prophylaxis and therapy of conditions whose course involves an increased activity of matrix-degrading enzymes, in particular stromelysin.

## Claims

### Claim 1

A compound of the formula I 4
wherein R1 is selected from
a (C3-C10) linear or branched aklyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
—OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
NR4R5 where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
a halogen;
═O; and
—COOH;; and
a (C3-C10) linear or branched alkenyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
—OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
NR4R5 where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
a halogen;
═O; and
—COOH;;
R2 is selected from
a (C3-C10) linear or branched aklyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
—OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
NR4R5, where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
a halogen;
═O; and
—COOH; and
a (C3-C10) linear or branched alkenyl group which is unsubstituted or monosubstituted, disubstituted, or trisubstituted with a group selected from
—OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
NR4R5, where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
a halogen;
═O; and
—COOH; and
Z is a hexose which is in pyranoid form via a C-glycosidic bond, or a stereoiosmer or physiologically tolerable salt thereof.

### Claim 2 (depends on 1)

A compound of the formula I as claimed in claim 1, wherein
R1 is nonadienyl,
R2 is nonadienyl and
Z is selected from D(+)-glucose, D(+)-mannose, D(+)-galactose, and D(+)-talose.

### Claim 3

The compound stromemycin having the following structure 5

### Claim 4 (depends on 3)

A process for a preparing a compound of claim 3 comprising
a) culturing a microorganism selected from DSM12038, mutants of DSM12038, and variants of DSM12038 in an aqueous nutrient medium; and
b) isolating stromemycin.

### Claim 5 (depends on 4)

A process according to claim 4 further comprising purifying stromemycin.

### Claim 6 (depends on 1, 3)

A process for preparing a compound of formula I of claim 1 comprising reductively hydrogenating the compound of claim 3 under sufficient conditions wherein R1 and R2 of formula I are together C9-alkyls to form a compound of formula I.

### Claim 7 (depends on 2, 3)

A process for preparing a compound of formula I of claim 2 comprising ozonolysis of the compound of claim 3 under sufficient conditions wherein R1 and R2 are together selected from —CH2CH2CH2OH, —CH2CH2CHO, and —CH2CH2COOH to form a compound of formula I.

### Claim 8 (depends on 1, 3)

A process for preparing a compound of formula I of claim 1 comprising ozonolysis of the compound of claim 3 under sufficient conditions wherein R1 and R2 are together selected from —CH2CH2CH2OH, —CH2CH2CHO, and —CH2CH2COOH to form a compound of formula I.

### Claim 9 (depends on 2, 3)

A process for preparing a compound of formula I of claim 2 comprising ozonolysis of the compound of claim 3 under sufficient conditions wherein R1 and R2 are together selected from —CH2CH2CH2OH, —CH2CH2CHO, and —CH2CH2COOH to form a compound of formula I.

### Claim 10 (depends on 8)

A process according to claim 8 further comprising treating the compound of formula I with at least one alkylidenephosphorane under sufficient conditions to extend R1 and R2 by 1, 2, 3, 4, 5, 6, or 7 methylene groups wherein the methylene groups are bonded to least one functional group selected from hydroxyl, ether, fluorine, chlorine, bromine, iodine, an amino group, and methyl.

### Claim 11 (depends on 9)

A process according to claim 9 further comprising treating the compound of formula I with at least one alkylidenephosphorane under sufficient conditions to extend R1 and R2 by 1, 2, 3, 4, 5, 6, or 7 methylene groups wherein the methylene groups are bonded to least one functional group selected from hydroxyl, ether, fluorine, chlorine, bromine, iodine, an amino group, and methyl.

### Claim 12 (depends on 8)

A process according to claim 8 further comprising separating the compound of formula I into component enantiomers by treating with at least one reagent selected from enantiomerically pure acids and enantiomerically pure bases.

### Claim 13 (depends on 8)

A process according to claim 8 further comprising separating the compound of formula I into component enantiomers by chromatography on chiral stationary phases.

### Claim 14 (depends on 8)

A process according to claim 8 further comprising derivatizing the compound of formula I with chiral entantiomerically pure compounds selected from at least one amino acid to form diastereomers with chiral auxiliary groups; separating the diaestereomers under sufficient conditions; and removing the chiral auxiliary groups under sufficient conditions.

### Claim 15 (depends on 5)

A process according to claim 5 further comprising treating stromemycin with an acid or base to form a physiologically acceptable salt.

### Claim 16 (depends on 6, 7, 8, 9, 10, 11, 12, 13)

A process according to claims 6, 7, 8, 9, 10, 11, 12, 13, or 14 further comprising treating the compound of formula I with an acid or base to form a physiologically acceptable salt.

### Claim 17 (depends on 1)

A pharmaceutical composition according to claim 1 comprising a compound of formula I and at least one excipient.

### Claim 18 (depends on 2)

A pharmaceutical composition according to claim 2 comprising a compound of formula I and at least one excipient.

### Claim 19 (depends on 3)

A pharmaceutical composition comprising a compound of claim 3 and at least one excipient.

### Claim 20 (depends on 17)

A pharmaceutical composition according to claim 17 further comprising an active ingredient other than a compound of formula I, and a pharmaceutically suitable and physiologically tolerable vehicle.

### Claim 21

A method of treatment or prophylaxis of conditions involving increased activity of matrix-degrading metalloproteinases comprising administering a pharmaceutically effective amount of a compound of formula I to an animal or human host in need thereof.

### Claim 22

A method of treatment or prophylaxis of conditions involving increased activity of matrix-degrading metalloproteinases comprising administering a pharmaceutically effective amount of stromemycin to an animal or human host in need thereof.

### Claim 23

A method for treating tissue disorders selected from osteoarthrosis, spondylosis, chondrolysis after joint trauma or relatively long joint immobilization after meniscus or patella injuries or tearing of the ligaments, collagenoses, periodontal conditions, wound healing disorders, chronic conditions of the locomotory apparatus, inflammatorily, immunologically or metabolically caused acute and chronic arthritis, arthropathy, myalgia, disorders of the bone metabolism, ulceration, atherosclerosis, stenoses, inflammation, carcinomatous disorders, formation of tumor metasases, cachexia, anorexia, and septic shock comprising administering a pharmaceutically acceptable amount of a compound of formula I to an animal or human host in need thereof.

### Claim 24

A method for treating tissue disorders selected from osteoarthrosis, spondylosis, chondrolysis after joint trauma or relatively long joint immobilization after meniscus or patella injuries or tearing of the ligaments, collagenoses, periodontal conditions, wound healing disorders, chronic conditions of the locomotory apparatus, inflammatorily, immunologically or metabolically caused acute and chronic arthritis, arthropathy, myalgia, disorders of the bone metabolism, ulceration, atherosclerosis, stenoses, inflammation, carcinomatous disorders, formation of tumor metasases, cachexia, anorexia, and septic shock comprising administering a pharmaceutically acceptable amount of stromemycin to an animal or human host in need thereof.
